Related Experiment Video
Updated: Jun 10, 2026
06:52
Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
[Amyloid PET in Alzheimer research]
1Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo, Japan.
Brain and Nerve = Shinkei Kenkyu No Shinpo
|August 3, 2010
Summary
Amyloid positron emission tomography (PET) visualizes amyloid-beta buildup in the brain, aiding early Alzheimer's disease (AD) diagnosis and tracking treatment effectiveness. PiB-PET studies reveal amyloid accumulation begins in preclinical AD stages.
Area of Science:
- Neuroimaging
- Neuropathology
- Biomarker Development
Background:
- Amyloid positron emission tomography (PET) is a non-invasive technique for visualizing fibrillar amyloid-beta deposition in the brain.
- Pittsburgh compound-B (PiB) is a widely accepted amyloid PET tracer.
- Amyloid-beta accumulation is implicated in the pathogenesis of Alzheimer's disease (AD).
Purpose of the Study:
- To review the role of amyloid PET, particularly PiB-PET, in Alzheimer's disease research.
- To explore amyloid-beta as a biomarker for early AD diagnosis and therapeutic monitoring.
- To discuss the implications of amyloid PET findings in various cognitive stages and related disorders.
Main Methods:
- Review of evidence from PiB-PET studies.
- Analysis of amyloid-beta accumulation patterns across disease stages (preclinical, mild cognitive impairment).
- Comparison of amyloid PET findings with clinical diagnoses and genetic factors (APOE4).
Main Results:
- Amyloid-beta accumulation begins in preclinical AD and plateaus by mild cognitive impairment.
- Positive amyloid PET results in amnestic mild cognitive impairment predict AD conversion.
- Amyloid PET can differentiate AD from other tauopathies and reveals APOE4's role in accelerating amyloid deposition.
- Cognitively normal individuals can be amyloid PET-positive.
Conclusions:
- Amyloid PET, especially with PiB, is a valuable tool for early AD detection and monitoring treatment efficacy.
- Amyloid-beta serves as a potential biomarker for AD progression and therapeutic response.
- Further prospective and comparative studies are essential to fully elucidate the clinical significance of amyloid PET findings.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...